LICENSE AGREEMENTLicense Agreement • March 3rd, 2022 • HUTCHMED (China) LTD • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (this “Agreement”) is made and entered into as of August 7, 2021 (“Effective Date”) between Epizyme, Inc., a corporation organized and existing under the laws of the State of Delaware, with a principal place of business at 400 Technology Square, Cambridge, Massachusetts 02139 U.S. (“Epizyme”), and Hutchison China MediTech Investment Limited, a company organized and existing under the laws of the British Virgin Islands, with company number 2031179 and its registered office being Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands (“Hutchmed”). Epizyme and Hutchmed may be referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT TO THE AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • March 3rd, 2022 • HUTCHMED (China) LTD • Pharmaceutical preparations
This Amendment (the “Amendment”) to the Amended and Restated License and Collaboration Agreement dated December 7th, 2020 (collectively, the “Agreement”) and made by and between:
DATE]PRIVATE & CONFIDENTIAL [NAME] Present Dear NAME,HUTCHMED (China) LTD • March 3rd, 2022 • Pharmaceutical preparations • New Jersey
This is to confirm our offer of employment (the “Agreement”) to you as [TITLE]. You will be employed by Hutchison MediPharma (US), Inc. (“the Company”) under the following terms and conditions with effect from [DATE] (the “Effective Date”) :-
